Clin Lab. 2020 Apr 1;66(4). doi: 10.7754/Clin.Lab.2019.190217.
To analyze the differences in gene expression levels of chemokine CXCL-12 and its receptor CXCR4 in gastric cancer and the relationship between their correlations with the clinical prognosis of gastric cancer.
The information on gastric cancer in the TCGA (The Cancer Genome Atlas) database was downloaded from the Broad GDAC FIREHOSE, including CXCL-12 and CXCR4 gene expression data of 415 gastric cancer tissues and 35 normal gastric tissues; clinical information of 392 gastric cancer cases. All patients were divided into either a correlated (significantly higher or lower correlation between CXCL12 and CXCR4 expression) or uncorrelated groups. Wilcoxon rank sum test was used to analyze the differential gene expressions of CXCL-12 and CXCR4 between gastric cancer tissues and normal gastric tissues. Furthermore, one-way analysis of variance and Kaplan-Meier survival analysis were used to analyze the differential gene expressions of CXCL-12 and CXCR4 and the prognosis in patients with different stages of gastric cancer. Gastric cancer patients were divided into two groups according to whether CXCL-12 and CXCR4 gene expressions were correlated or not. Kaplan-Meier survival analysis was used to analyze the three-year survival of the two groups.
There were differences between CXCL-12 and CXCR4 expression in 415 gastric cancer tissues and 35 normal gastric tissues. No statistically significant difference between CXCL-12 and CXCR4 was detected in different stages of gastric cancer. There were differences of the five-year survival in different stages of gastric cancer. Further analysis showed that the three-year survival in the correlated group was superior compared to the uncor-related one.
The gene expression of CXCL-12 and CXCR4 was significantly different between gastric cancer tissues and normal gastric tissues. Moreover, the correlation between CXCL-12 and CXCR4 gene expression may be used as a predictor of clinical prognosis in patients with gastric cancer.
分析趋化因子 CXCL-12 及其受体 CXCR4 在胃癌中的基因表达水平差异及其与胃癌临床预后的关系。
从 Broad GDAC FIREHOSE 下载 TCGA（癌症基因组图谱）数据库中的胃癌信息，包括 415 例胃癌组织和 35 例正常胃组织的 CXCL-12 和 CXCR4 基因表达数据；392 例胃癌病例的临床资料。所有患者分为相关（CXCL12 和 CXCR4 表达明显相关）或不相关组。Wilcoxon 秩和检验分析胃癌组织和正常胃组织中 CXCL-12 和 CXCR4 的差异基因表达。进一步采用单因素方差分析和 Kaplan-Meier 生存分析，分析不同分期胃癌患者 CXCL-12 和 CXCR4 的差异基因表达与预后的关系。根据 CXCL-12 和 CXCR4 基因表达是否相关，将胃癌患者分为两组。采用 Kaplan-Meier 生存分析分析两组患者的 3 年生存率。
415 例胃癌组织和 35 例正常胃组织中 CXCL-12 和 CXCR4 的表达存在差异。不同分期胃癌患者 CXCL-12 和 CXCR4 无统计学差异。不同分期胃癌患者 5 年生存率存在差异。进一步分析显示，相关组的 3 年生存率优于不相关组。
胃癌组织中 CXCL-12 和 CXCR4 的基因表达存在显著差异。而且，CXCL-12 和 CXCR4 基因表达的相关性可作为胃癌患者临床预后的预测指标。
